{"name":"Taejoon Pharmaceutical Co., Ltd.","slug":"taejoon-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"CTP0302-B","genericName":"CTP0302-B","slug":"ctp0302-b","indication":"Type 2 diabetes","status":"phase_3"},{"name":"CTP0301-A","genericName":"CTP0301-A","slug":"ctp0301-a","indication":"Type 2 diabetes","status":"phase_3"},{"name":"CTP0301-B","genericName":"CTP0301-B","slug":"ctp0301-b","indication":"Type 2 diabetes","status":"phase_3"},{"name":"CTP0302-A","genericName":"CTP0302-A","slug":"ctp0302-a","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Coolprep powder","genericName":"Coolprep powder","slug":"coolprep-powder","indication":"Hypercholesterolemia","status":"phase_3"},{"name":"TJO-002","genericName":"TJO-002","slug":"tjo-002","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TJO-083","genericName":"TJO-083","slug":"tjo-083","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TJO-087","genericName":"TJO-087","slug":"tjo-087","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TJP-008-1","genericName":"TJP-008-1","slug":"tjp-008-1","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TJP-008-2","genericName":"TJP-008-2","slug":"tjp-008-2","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"CTP0303","genericName":"CTP0303","slug":"ctp0303","indication":"Other","status":"phase_3"},{"name":"Conventional OST","genericName":"Conventional OST","slug":"conventional-ost","indication":"Bone defects and fracture healing","status":"phase_3"},{"name":"CTO0303-B","genericName":"CTO0303-B","slug":"cto0303-b","indication":"Other","status":"phase_2"},{"name":"Cool prep","genericName":"Cool prep","slug":"cool-prep","indication":"Bowel cleansing prior to colonoscopy","status":"phase_3"},{"name":"Taflotan-S","genericName":"Taflotan-S","slug":"taflotan-s","indication":"Other","status":"marketed"},{"name":"Xalost S","genericName":"Xalost S","slug":"xalost-s","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Diquafosol ophthalmic sodium solution 3%","genericName":"Diquafosol ophthalmic sodium solution 3%","slug":"diquafosol-ophthalmic-sodium-solution-3","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Cyclosporine ophthalmic solution 0.05%","genericName":"Cyclosporine ophthalmic solution 0.05%","slug":"cyclosporine-ophthalmic-solution-0-05","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"TJO-018 (HA 0.15%)","genericName":"TJO-018 (HA 0.15%)","slug":"tjo-018-ha-0-15","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Orafang Tab","genericName":"Orafang Tab","slug":"orafang-tab","indication":"Thromboembolism prevention (specific indication under Phase 3 evaluation)","status":"phase_3"}]}],"pipeline":[{"name":"CTP0302-B","genericName":"CTP0302-B","slug":"ctp0302-b","phase":"phase_3","mechanism":"CTP0302-B is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CTP0303","genericName":"CTP0303","slug":"ctp0303","phase":"phase_3","mechanism":"CTP0303 is an investigational therapeutic in phase 3 development by Taejoon Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"Conventional OST","genericName":"Conventional OST","slug":"conventional-ost","phase":"phase_3","mechanism":"Conventional OST (Osteogenic Stem Cell Therapy) promotes bone formation and regeneration by utilizing osteogenic stem cells to stimulate new bone growth.","indications":["Bone defects and fracture healing"],"catalyst":""},{"name":"Diquafosol ophthalmic sodium solution 3%","genericName":"Diquafosol ophthalmic sodium solution 3%","slug":"diquafosol-ophthalmic-sodium-solution-3","phase":"phase_3","mechanism":"Diquafosol is a P2Y2 purinergic receptor agonist that stimulates secretion of mucin and aqueous fluid from conjunctival and lacrimal glands to increase tear production.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"CTO0303-B","genericName":"CTO0303-B","slug":"cto0303-b","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CTP0301-A","genericName":"CTP0301-A","slug":"ctp0301-a","phase":"phase_3","mechanism":"CTP0301-A is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CTP0301-B","genericName":"CTP0301-B","slug":"ctp0301-b","phase":"phase_3","mechanism":"CTP0301-B is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CTP0302-A","genericName":"CTP0302-A","slug":"ctp0302-a","phase":"phase_3","mechanism":"CTP0302-A is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Cool prep","genericName":"Cool prep","slug":"cool-prep","phase":"phase_3","mechanism":"Cool prep is a bowel preparation agent designed to cleanse the colon prior to colonoscopy procedures.","indications":["Bowel cleansing prior to colonoscopy"],"catalyst":""},{"name":"Coolprep powder","genericName":"Coolprep powder","slug":"coolprep-powder","phase":"phase_3","mechanism":"Coolprep powder is a medication used to treat hypercholesterolemia by inhibiting the absorption of dietary cholesterol.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"Cyclosporine ophthalmic solution 0.05%","genericName":"Cyclosporine ophthalmic solution 0.05%","slug":"cyclosporine-ophthalmic-solution-0-05","phase":"phase_3","mechanism":"Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye.","indications":["Dry eye disease (keratoconjunctivitis sicca)","Ocular inflammation associated with dry eye"],"catalyst":""},{"name":"Orafang Tab","genericName":"Orafang Tab","slug":"orafang-tab","phase":"phase_3","mechanism":"Orafang is an oral anticoagulant that inhibits Factor Xa in the coagulation cascade to prevent thrombus formation.","indications":["Thromboembolism prevention (specific indication under Phase 3 evaluation)"],"catalyst":""},{"name":"TJO-002","genericName":"TJO-002","slug":"tjo-002","phase":"phase_3","mechanism":"TJO-002 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TJO-018 (HA 0.15%)","genericName":"TJO-018 (HA 0.15%)","slug":"tjo-018-ha-0-15","phase":"marketed","mechanism":"TJO-018 is a hyaluronic acid-based topical formulation that provides lubrication and moisture retention to the ocular surface.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"TJO-083","genericName":"TJO-083","slug":"tjo-083","phase":"phase_3","mechanism":"TJO-083 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TJO-087","genericName":"TJO-087","slug":"tjo-087","phase":"phase_3","mechanism":"TJO-087 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TJP-008-1","genericName":"TJP-008-1","slug":"tjp-008-1","phase":"phase_3","mechanism":"TJP-008-1 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TJP-008-2","genericName":"TJP-008-2","slug":"tjp-008-2","phase":"phase_3","mechanism":"TJP-008-2 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Taflotan-S","genericName":"Taflotan-S","slug":"taflotan-s","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Xalost S","genericName":"Xalost S","slug":"xalost-s","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOVUJNbU51Zllfa3VSWGp5YkxGd0hEd3A0QXlmLW1hRmZ3THVxOFFPU1ZkY0NRc1FQMXlHWHd5MmEzTGtqUU5iTzJPX1RCVlRScGtoWjFqaDB5X0xXd0RLTUJEdHRqRGJpRUQwNFJmcjRCdzFrN05CckI0MmFzZTBQZjVWQVpzWkRJbThybXV3NmgyanU2NDRHTEFaaGd5SGpsR1VJQnEtY2ViZEVkZXpFYnVwTjg0MU5WVGljSXlFS1RhLU1xbVJ4anVpWmkwQQ?oc=5","date":"2026-03-18","type":"pipeline","source":"vocal.media","summary":"Contrast Media Market: Precision Medicine Trends, Low-Osmolar Iodinated Agents, & Industry Growth Outlook - vocal.media","headline":"Contrast Media Market: Precision Medicine Trends, Low-Osmolar Iodinated Agents, & Industry Growth Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBCYjJQLVNFSzVsODZDOTFydmw1OUEzMGU3dXFhOU9HMHVqZEVKZ1dHYWNLUTFYeXFpNjdwS3F6UDVzZU1tQS1lQU1MOVBEc1FubElsWEFkTWdlZ2tPREduQW5IdzdsYXM?oc=5","date":"2026-03-11","type":"pipeline","source":"Precedence Research","summary":"Contrast Media Market Size to Hit USD 16.54 Billion by 2035 - Precedence Research","headline":"Contrast Media Market Size to Hit USD 16.54 Billion by 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQckh3eDhZN2dBSDNaVDdIU2YxeE9nRmt2VUZILXcxb2VudFhOQzFUUlZLMUhxSk94TFphMnhCYUNCamRBLUVFSUxBYi15a3lWVlYwRFRrb0J3SzdKSm9XNE5NODJsenRIN21DdkJETXlvclc4dFRIWDU3Wm9ZbDZBMGdZRzd5Z3lET0NacEtmVldDVWVkZmxVa1YyUzNGeWdRRU9ral9oRHk2N0hUU0NuT2F4enQ?oc=5","date":"2024-02-20","type":"pipeline","source":"PR Newswire","summary":"Contrast Media Market Worth $9.7 Billion | MarketsandMarkets™. - PR Newswire","headline":"Contrast Media Market Worth $9.7 Billion | MarketsandMarkets™.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPWUJjSm5jTGUyblljZS0yWVl4bGZwa1FVeUlHMlh1LVQyTUdxdl9UZGFDa2FYbjlSVU90LUtVeFFYdTBrVV9fWWZsLTFLUW9jblkyQ2NPR0xKU3FGZ0VpVnJfV2pCLUtpNkNEa2ROcTZnYi12Z2dUSlhsYXNpNFB2S2RvNnpDdw?oc=5","date":"2022-10-11","type":"pipeline","source":"Yahoo Finance","summary":"[Latest] Global MRI Contrast Agents Market Size Worth 4.54 Billion by 2030 at a 6.2% CAGR: Custom Market Insights (Share, Report, Trends, Forecast, Trends, Segmentation) - Yahoo Finance","headline":"[Latest] Global MRI Contrast Agents Market Size Worth 4.54 Billion by 2030 at a 6.2% CAGR: Custom Market Insights (Share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQaTdTSzRiV3NFODRLTkNjZkZwSWtLSUtCbnl4Z1hzal9peWVxSFJoQVJ4d2hERUVCMmZxMmUwNVFibVJ2SnZXLUZZend5dEdBWnNwdWpBWTNkNm1lWHhPUWNOQ0dKT2xLcDhkeU4xZDdnM2paWWZxU1l2SVBBSW4wM1VGU2hkUQ?oc=5","date":"2016-03-31","type":"pipeline","source":"MarketsandMarkets","summary":"Contrast Media Market Report 2026-2031, By Type, Form, and Geo - MarketsandMarkets","headline":"Contrast Media Market Report 2026-2031, By Type, Form, and Geo","sentiment":"neutral"}],"patents":[],"drugCount":20,"phaseCounts":{"phase_3":16,"phase_2":1,"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}